Melanotan I Explained
Melanotan I is a man-made copy of a hormone your body naturally makes called alpha-MSH. Think of it as a messenger that tells your skin cells to ramp up their tanning response. It's actually approved as a medical treatment in Europe and Australia—specifically for people with a rare genetic condition where sunlight triggers severe, painful reactions. But beyond that, people are interested in it because it essentially pre-tans your skin before you're even exposed to the sun.
Here's how it works: Your skin contains special cells called melanocytes that produce melanin—the pigment that makes you tan. Melanotan I acts like a very specific key that fits into a particular lock on these cells called the MC1R receptor. When it turns this lock, your melanocytes go into overdrive producing extra melanin, the dark protective kind your body naturally makes. This darkens your skin and boosts its natural defense against UV damage. For people with that rare sun-sensitivity condition, this pre-emptive darkening is genuinely protective. What makes Melanotan I different from similar peptides is that it's highly selective—it only targets the skin cells, so you get the tanning effect without weird side effects in your brain or elsewhere in your body.
Dosage Information
Typical Dose
16 mg implant (FDA/EMA approved dose for EPP)
Frequency
Implant replaced every 2 months
Administration
Subcutaneous implant (approved use) or injection (research use)
Half-Life
~30 minutes
Notes
Approved as a slow-release implant for EPP. Research use of injectable form for tanning is off-label and unregulated. The implant provides sustained low-level release over 60 days.
Why this matters
Shorter than MT-II; clinical analog afamelanotide uses implant for sustained release.
Protocol cycle
Dose Calculator
Calculate your draw amount for an insulin syringe (U-100)
Concentration: 2,500 mcg/mL
Sign in to save your reconstitution settings for this peptide
Draw to the
640
unit mark
Draw 640 units for your 16000mcg dose of Melanotan I
This calculator is for educational purposes. Always verify your calculations and consult a healthcare professional.
Where does Melanotan I sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.74
Compound Data
Molecular Formula
C78H111N21O19
Molecular Weight
1646.80 g/mol
IUPAC Name
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-6-amino-1-[(2S)-2-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxohexan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
PubChem CID
16197727Potential Side Effects
Melanotan I discussions
Quick Facts
- Administration
- Subcutaneous implant (approved use) or injection (research use)
- Typical Dose
- 16 mg implant (FDA/EMA approved dose for EPP)
- Frequency
- Implant replaced every 2 months
- References
- 0 curated + 47 from PubMed
- Clinical Trials
- 23 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Melanotan I
What is Melanotan I?
Melanotan I (Afamelanotide) is a synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analog approved in Europe and Australia under the brand name Scenesse as an implant for prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). Unlike Melanotan II it is more selective for MC1R and does not significantly activate MC3R MC4R or MC5R meaning it produces skin darkening without the sexual side effects associated with Melanotan II. It has completed multiple Phase 3 clinical trials and has regulatory approval making it one of the few melanocortin peptides with an established clinical evidence base.
How does Melanotan I work?
Melanotan I acts primarily as a selective MC1R agonist on melanocytes — the pigment-producing cells in the skin. MC1R activation stimulates the production and release of eumelanin the dark brown-black form of melanin that provides UV protection. By increasing eumelanin production prior to sun exposure Melanotan I effectively pre-tans the skin and increases its natural UV photoprotection. In the EPP indication this protection from UV-triggered protoporphyrin accumulation reduces the severe phototoxic pain attacks that characterize the condition. The selectivity for MC1R over MC4R means Melanotan I does not produce the central sexual and appetite-modulating effects seen with non-selective melanocortin agonists like Melanotan II.
What is the recommended dosage for Melanotan I?
The typical dose is 16 mg implant (FDA/EMA approved dose for EPP). Implant replaced every 2 months. Administration: Subcutaneous implant (approved use) or injection (research use). Approved as a slow-release implant for EPP. Research use of injectable form for tanning is off-label and unregulated. The implant provides sustained low-level release over 60 days.
What are the side effects of Melanotan I?
Nausea (common, transient). Hyperpigmentation of existing nevi — moles may darken (common). Fatigue (uncommon). Injection/implant site reactions (uncommon). Spontaneous erections in men at higher doses (uncommon)
What is the Melanotan I cycle protocol?
Melanotan I is typically cycled continuous. Implant replaced every 2 months; sustained release
Questions reflect common community inquiries. This is not medical advice.